AstraZeneca's Prilosec OTC suit deemed "frivolous"
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca must pay Dr. Reddy's attorneys' fees for a patent infringement case, says Judge Colleen McMahon of the U.S. District Court for the Southern District of New York. She writes in a March 30 1decision that AstraZeneca lacked evidence that Dr. Reddy's abbreviated new drug application for a Prilosec OTC equivalent infringed its patents. "I certainly hope that this ruling chills the sort of unreasonable, frivolous, anti-competitive, anti-consumer litigation in which plaintiffs here engaged," McMahon writes. Dr. Reddy's won the suit in March 2009, but did not launch its generic omeprazole capsule until late 2009 (2"The Tan Sheet" Dec. 21, 2009, In Brief)
You may also be interested in...
Dr. Reddy's Prilosec OTC generic arrives
The first major competition for Perrigo's private-label proton pump inhibitor hits shelves after a delay, Dr. Reddy's says. Perrigo has said it does not expect the India-based generics firm's capsule version of Procter & Gamble's Prilosec OTC to substantially affect sales of its own omeprazole tablet (1"The Tan Sheet" Nov. 9, 2009). In a Dec. 15 note, Collins Stewart analyst Louise Chen points out Perrigo has an 18-month head start on Dr. Reddy's, which she expects will only "take modest market share away" from Perrigo. A same-day Goldman Sachs report says Perrigo expects to maintain annual omeprazole sales of over $200 million, assuming an 80-percent to 90-percent share of the generic Prilosec OTC market, which itself is approaching 50 percent of all OTC omeprazole
FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions
Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.
Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms
Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.